Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash from Financing Activities (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Cash from Financing Activities data on record, last reported at $93.5 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 14458.41% year-over-year to $93.5 million; the TTM value through Dec 2025 reached $112.7 million, up 3.38%, while the annual FY2025 figure was $112.7 million, 3.38% up from the prior year.
  • Cash from Financing Activities reached $93.5 million in Q4 2025 per CTNM's latest filing, up from $19.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $108.4 million in Q2 2024 and bottomed at -$617000.0 in Q1 2023.
  • Average Cash from Financing Activities over 3 years is $23.2 million, with a median of $366500.0 recorded in 2024.
  • The widest YoY moves for Cash from Financing Activities: up 146861.54% in 2025, down 99.92% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at -$321000.0 in 2023, then surged by 300.0% to $642000.0 in 2024, then surged by 14458.41% to $93.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $93.5 million in Q4 2025, $19.1 million in Q3 2025, and $91000.0 in Q2 2025.